CA3092255A1 - Dihydrochromene derivatives - Google Patents
Dihydrochromene derivatives Download PDFInfo
- Publication number
- CA3092255A1 CA3092255A1 CA3092255A CA3092255A CA3092255A1 CA 3092255 A1 CA3092255 A1 CA 3092255A1 CA 3092255 A CA3092255 A CA 3092255A CA 3092255 A CA3092255 A CA 3092255A CA 3092255 A1 CA3092255 A1 CA 3092255A1
- Authority
- CA
- Canada
- Prior art keywords
- pyrano
- benzopyran
- piperidine
- spiro
- dimethy1
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/20—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Compositions Of Macromolecular Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2018-052971 | 2018-03-20 | ||
| JP2018052971 | 2018-03-20 | ||
| PCT/JP2019/011439 WO2019181939A1 (ja) | 2018-03-20 | 2019-03-19 | ジヒドロクロメン誘導体 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3092255A1 true CA3092255A1 (en) | 2019-09-26 |
Family
ID=67986459
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3092255A Pending CA3092255A1 (en) | 2018-03-20 | 2019-03-19 | Dihydrochromene derivatives |
Country Status (21)
| Country | Link |
|---|---|
| US (3) | US10807993B2 (https=) |
| EP (1) | EP3770162B1 (https=) |
| JP (4) | JP6733072B2 (https=) |
| KR (1) | KR102799186B1 (https=) |
| CN (1) | CN111886237B (https=) |
| AU (1) | AU2019239481B2 (https=) |
| CA (1) | CA3092255A1 (https=) |
| CY (1) | CY1126034T1 (https=) |
| DK (1) | DK3770162T3 (https=) |
| EA (1) | EA202092206A1 (https=) |
| ES (1) | ES2941771T3 (https=) |
| FI (1) | FI3770162T3 (https=) |
| HU (1) | HUE062256T2 (https=) |
| MX (1) | MX2020009763A (https=) |
| MY (1) | MY202583A (https=) |
| PH (1) | PH12020551497A1 (https=) |
| PL (1) | PL3770162T3 (https=) |
| PT (1) | PT3770162T (https=) |
| SG (1) | SG11202007979UA (https=) |
| TW (1) | TWI899051B (https=) |
| WO (1) | WO2019181939A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL3770162T3 (pl) * | 2018-03-20 | 2023-06-05 | Sumitomo Pharma Co., Ltd. | Pochodne dihydrochromenu |
| GB201905721D0 (en) | 2019-04-24 | 2019-06-05 | Univ Dundee | Compounds |
| WO2025100519A1 (ja) * | 2023-11-09 | 2025-05-15 | 住友ファーマ株式会社 | ジヒドロクロメン誘導体を含むがんの治療剤 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001045707A1 (en) | 1999-12-21 | 2001-06-28 | Merck & Co., Inc. | Inhibitors of prenyl-protein transferase |
| US20090111805A1 (en) | 2005-02-24 | 2009-04-30 | Pfizer Inc. | Bicyclic heteroaromatic derivatives useful as anticancer agents |
| US20080255149A1 (en) * | 2005-09-27 | 2008-10-16 | Novartis Ag | Carboxyamine Compounds and Methods of Use Thereof |
| EP1847542A1 (en) | 2006-04-21 | 2007-10-24 | Laboratorios del Dr. Esteve S.A. | Spiro[benzopyran] or spiro[benzofuran] derivatives which inhibit the sigma receptor |
| HRP20160625T1 (hr) * | 2007-09-10 | 2016-08-12 | Boston Biomedical, Inc. | Novi inhibitori stat3 signalnog puta i inhibitori matičnih stanica raka |
| RU2018101897A (ru) * | 2015-06-22 | 2019-07-24 | Сумитомо Дайниппон Фарма Ко., Лтд. | Бициклическое гетероциклическое амидное производное |
| CA2990583A1 (en) | 2015-06-22 | 2016-12-29 | Sumitomo Dainippon Pharma Co., Ltd. | 1,4-disubstituted imidazole derivative |
| JP6896701B2 (ja) * | 2016-02-26 | 2021-06-30 | 大日本住友製薬株式会社 | イミダゾリルアミド誘導体 |
| TW201821105A (zh) * | 2016-10-20 | 2018-06-16 | 美商弗瑪治療公司 | 使用ｈｄａｃ１１抑制劑之方法 |
| PL3770162T3 (pl) | 2018-03-20 | 2023-06-05 | Sumitomo Pharma Co., Ltd. | Pochodne dihydrochromenu |
| JP2020019752A (ja) | 2018-08-03 | 2020-02-06 | 大日本住友製薬株式会社 | クロマン誘導体 |
-
2019
- 2019-03-19 PL PL19770755.7T patent/PL3770162T3/pl unknown
- 2019-03-19 TW TW108109362A patent/TWI899051B/zh active
- 2019-03-19 AU AU2019239481A patent/AU2019239481B2/en active Active
- 2019-03-19 PT PT197707557T patent/PT3770162T/pt unknown
- 2019-03-19 MX MX2020009763A patent/MX2020009763A/es unknown
- 2019-03-19 SG SG11202007979UA patent/SG11202007979UA/en unknown
- 2019-03-19 MY MYPI2020004784A patent/MY202583A/en unknown
- 2019-03-19 WO PCT/JP2019/011439 patent/WO2019181939A1/ja not_active Ceased
- 2019-03-19 HU HUE19770755A patent/HUE062256T2/hu unknown
- 2019-03-19 FI FIEP19770755.7T patent/FI3770162T3/fi active
- 2019-03-19 EP EP19770755.7A patent/EP3770162B1/en active Active
- 2019-03-19 CN CN201980020335.0A patent/CN111886237B/zh active Active
- 2019-03-19 EA EA202092206A patent/EA202092206A1/ru unknown
- 2019-03-19 DK DK19770755.7T patent/DK3770162T3/da active
- 2019-03-19 KR KR1020207029401A patent/KR102799186B1/ko active Active
- 2019-03-19 ES ES19770755T patent/ES2941771T3/es active Active
- 2019-03-19 CA CA3092255A patent/CA3092255A1/en active Pending
- 2019-03-19 JP JP2020507833A patent/JP6733072B2/ja active Active
-
2020
- 2020-03-03 US US16/808,246 patent/US10807993B2/en active Active
- 2020-07-08 JP JP2020117566A patent/JP7247144B2/ja active Active
- 2020-07-31 US US16/944,482 patent/US11639357B2/en active Active
- 2020-09-18 PH PH12020551497A patent/PH12020551497A1/en unknown
-
2023
- 2023-03-15 JP JP2023040667A patent/JP7508620B2/ja active Active
- 2023-03-21 US US18/187,124 patent/US12398149B2/en active Active
- 2023-05-26 CY CY20231100250T patent/CY1126034T1/el unknown
-
2024
- 2024-06-19 JP JP2024098472A patent/JP2024123117A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11369605B2 (en) | Optically active azabicyclo ring derivative | |
| US12398149B2 (en) | Dihydrochromene derivatives | |
| US12364702B2 (en) | Highly active sting protein agonist compound | |
| US12559487B2 (en) | Crosslinked optically active secondary amine derivative | |
| ES2991898T3 (es) | Derivado de piperidina con puente ópticamente activo | |
| US10815241B2 (en) | Optically active azabicyclo ring derivative | |
| JP7287929B2 (ja) | ジヒドロクロメン誘導体を含有する医薬 | |
| JP2020019752A (ja) | クロマン誘導体 | |
| HK40043696B (en) | Dihydrochromene derivatives | |
| HK40043696A (en) | Dihydrochromene derivatives | |
| BR112020017481B1 (pt) | Derivados de di-hidrocromeno, seu uso e composição farmacêutica | |
| EA041753B1 (ru) | Производные дигидрохромена | |
| HK40048031A (en) | Highly active sting protein agonist compound |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20240313 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD Year of fee payment: 6 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250218 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20250218 Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250218 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20250311 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20250623 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250707 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20250724 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20250724 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - STANDARD Year of fee payment: 7 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20260204 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20260204 |